Login to Your Account

Riboquark enrolling pivotal study of siRNA ocular neuroprotectant in China

By David Ho
Staff Writer

Monday, November 20, 2017

HONG KONG – Kunshan Riboquark Pharmaceutical Technology Co. Ltd. enrolled the first patient in China for its global pivotal phase II/III study of ocular neuroprotectant candidate QPI-1007.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription